Ixazomib - lenalidomide - dexamethason in heavily pretreated multiple myeloma patients - case reports.
Ixazomib – lenalidomid – dexametazon u silně předléčených pacientů s mnohočetným myelomem – soubor kazuistik.
Kahler-Pick law
Multiple myeloma
ixazomib
leukaemia
leukemia
plasmacytoma
retreatment
Journal
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
ISSN: 1802-5307
Titre abrégé: Klin Onkol
Pays: Czech Republic
ID NLM: 9425213
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
20
4
2023
pubmed:
19
4
2023
entrez:
18
04
2023
Statut:
ppublish
Résumé
The treatment of aggressive multiple myeloma (MM) patients, resistant to several treatment modalities, is very difficult in the real-world-evidence conditions. Ixazomib is a second-generation oral proteasome inhibitor. In combination with lenalidomide and dexamethasone, it is an effective and low-toxic treatment regimen for patients with relapsed or refractory MM. The presented case reports of two patients with an aggressive course of MM demonstrate the surprising effectiveness of this regimen. Repeated treatment with a combination of proteasome inhibitors (ixazomib) and immunomodulatory drugs (lenalidomide) may lead to significant clinical benefit in some patients and should be considered even in end-stage disease patients.
Sections du résumé
BACKGROUND
BACKGROUND
The treatment of aggressive multiple myeloma (MM) patients, resistant to several treatment modalities, is very difficult in the real-world-evidence conditions. Ixazomib is a second-generation oral proteasome inhibitor. In combination with lenalidomide and dexamethasone, it is an effective and low-toxic treatment regimen for patients with relapsed or refractory MM.
OBSERVATION
METHODS
The presented case reports of two patients with an aggressive course of MM demonstrate the surprising effectiveness of this regimen.
CONCLUSION
CONCLUSIONS
Repeated treatment with a combination of proteasome inhibitors (ixazomib) and immunomodulatory drugs (lenalidomide) may lead to significant clinical benefit in some patients and should be considered even in end-stage disease patients.
Identifiants
pubmed: 37072251
pii: 133978
doi: 10.48095/ccko2023150
doi:
Substances chimiques
Lenalidomide
F0P408N6V4
ixazomib
71050168A2
Dexamethasone
7S5I7G3JQL
Proteasome Inhibitors
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM